const BLOG_POSTS = [
    {
        slug: 'benchmarks-tell-you-what-to-measure',
        title: 'Benchmarks Tell You What to Measure. But Who Verifies the Data Actually Meets the Benchmark?',
        excerpt: 'The AI data market is building standards. It\'s forgetting to build proof.',
        date: '2026-04-01',
        category: 'Data Licensing',
        featured: true,
        readTime: '10 min read',
        content: `The AI industry has a data problem everyone knows about and no one has solved.

Public training data is running out. The datasets that built GPT-4, Claude, and Gemini (Common Crawl, Wikipedia, open-access research papers) have been scraped, filtered, and recycled so many times that the marginal return on another pass is approaching zero. The frontier models being built today and tomorrow need something different: proprietary, domain-specific, real-world data locked inside hospitals, banks, law firms, and research institutions.

The problem is that these institutions can't just hand it over.

A hospital sitting on 20 years of clinical documentation doesn't have a "sell data" button. That data is governed by HIPAA, institutional review boards, patient consent frameworks, and internal compliance teams who will kill any deal that introduces custody risk. A financial institution with decades of transaction records faces the same wall: regulatory exposure, client confidentiality, competitive sensitivity. The data exists. The demand exists. But the transaction infrastructure doesn't.

The industry knows this. And it's starting to respond.

## The Benchmarking Wave

Over the past year, we've seen a push toward standardizing what "good" AI training data looks like. Companies are launching benchmark datasets, quality frameworks, and evaluation rubrics designed to give buyers confidence that the data they're purchasing is worth the price.

This is genuine progress. For years, AI data procurement was the Wild West. Buyers negotiating with brokers, relying on sample sets and NDAs, hoping the full dataset matched what they were promised. Benchmarks create a shared language. They let an AI lab say "we need data that meets X standard for completeness, Y standard for accuracy, Z standard for compliance coverage" and have that mean something concrete.

But benchmarks only solve one side of the equation.

A benchmark tells you what to measure. It defines the bar. It says "a high-quality clinical documentation dataset should have these properties." That's valuable. What it doesn't do, and what nothing in the current market does well, is let the institution prove their data clears that bar without exposing the data itself.

And that's where the entire system breaks down.

## The Trust Gap

Here's how a typical data licensing deal works today in a regulated industry:

An AI lab identifies that it needs clinical data for a healthcare model. It finds an institution willing to discuss licensing. The institution says their data is comprehensive, clean, and compliant. The AI lab says "prove it."

The direct path of the institutions licensing data to AI labs barely functions. When it's attempted, the process looks like this: NDAs get drafted, legal teams on both sides spend weeks negotiating terms, a sample set gets carefully curated and de-identified and reviewed by compliance, the AI lab evaluates a fraction of the actual dataset that may not be representative, asks for more, gets pushback, and months pass. Many of these deals collapse. Not because the data was bad or the price was wrong, but because neither side could verify the other's claims without taking on risk they weren't willing to accept.

But here's what's more telling than the deals that die: most institutions never even try.

The direct licensing path is so broken that an entire middleman industry has formed to route around it. Companies like Tempus, Truveta, Flatiron Health (acquired by Roche for $2.1 billion), Segmed, and Avandra now pay hospitals for de-identified patient data and resell it to AI labs and pharma companies. Tempus alone secured a $70 million deal with GSK. Truveta is building a 10-million-patient genome database sourced from health system partners. A January 2025 STAT News investigation documented the growing wave of companies lining up to buy patient records for AI training.

This intermediary model is the market's current answer to the trust problem. And it's a bad answer for almost everyone involved.

The institution sells de-identified data at a fraction of its real value and loses control over how it's used downstream. The AI lab gets data that's been stripped of the clinical context and granularity that made it valuable in the first place. De-identification removes the signal along with the risk. And the intermediary captures the margin that should have gone to the data's original owner. Meanwhile, HIPAA enforcement actions targeting AI are up 340%, and the regulatory walls are getting higher, not lower.

The system isn't just slow. It's structurally misaligned. The people who own the most valuable data have the least ability to monetize it, and the current workaround is selling to a middleman who strips it down and resells it, destroying value for both the institution and the end buyer.

Benchmarks don't fix this. You can define the most rigorous quality standard in the world, but if the only way to verify a dataset meets that standard is to look at the raw data, or trust a middleman who says they've already checked, then you haven't solved the fundamental problem. You've just added another layer of trust to a system that's failing because of trust.

## What Verification Actually Requires

The missing layer isn't better benchmarks. It's verification infrastructure: a way for a data provider to prove specific, measurable claims about their dataset without revealing the dataset itself, and a way for a data buyer to independently verify those claims before any transaction occurs.

This isn't a theoretical concept. The cryptographic primitives for this have existed for decades. Zero-knowledge proofs allow one party to prove a statement is true without revealing any information beyond the truth of the statement itself. In the context of data licensing, that means an institution can prove:

- Their dataset contains X number of records spanning Y time period
- The data meets specific completeness thresholds for required fields
- Compliance checks have been passed for defined regulatory frameworks
- The data has specific statistical properties relevant to the buyer's use case

All without the buyer ever seeing a single record. And the buyer doesn't have to take the institution's word for it. The proof is mathematically verifiable. Either the data has the claimed properties or it doesn't. There's no trust required.

This changes the economics of every data deal.

The institution doesn't need to prepare sample sets, negotiate NDAs for evaluation access, or worry about data exposure during the sales process. The AI lab doesn't need to rely on promises, spend months in legal review, or risk paying for data that doesn't match specifications. Both sides get what they need. The seller proves value, the buyer verifies quality, and neither side takes on unnecessary risk.

## Standards and Proof Are Two Halves of the Same Infrastructure

Here's what the market is getting wrong: it's treating benchmarking and verification as the same problem. They're not. They're complementary.

Benchmarks define what "good" looks like. They create the criteria, the checklist that a dataset needs to meet for a specific use case. That work is important and it's happening. The companies building quality standards for healthcare AI data, financial data, legal corpora, they're laying necessary groundwork.

But a standard without enforcement is just a suggestion. And in data markets, "enforcement" means the ability to independently verify that a specific dataset meets a specific standard, with mathematical certainty, before money changes hands.

The companies defining standards and the infrastructure that enforces verification aren't competitors. They're two layers of the same stack. One without the other leaves the same gap that's been killing data deals in regulated industries for years.

**Define the bar. Then prove you clear it.** That's how data markets actually scale.

## The Shift That's Coming

The AI training data market is valued at roughly $3.6 billion today and projected to exceed $23 billion by 2034. But that growth depends on institutions actually participating, and right now, most of them are on the sidelines. Not because they don't want to monetize their data. Because they can't do it without taking on risk that their compliance teams, their boards, and their regulators won't accept.

The infrastructure that unlocks institutional participation isn't a better marketplace. It's not a more trusted broker. It's a verification layer that removes the need for trust entirely. One that lets a hospital prove their clinical data meets an AI lab's requirements without exposing a single patient record. One that lets a financial institution demonstrate the depth and quality of their transaction data without opening themselves to competitive or regulatory risk.

**Benchmarks opened the conversation about data quality. Verification infrastructure is what will close the deals.**

That's the layer we're building at Aseryx. And if you're an institution sitting on decades of proprietary data you can't safely monetize, or an AI team spending months negotiating data access that should take days, this is the problem we want to solve with you.`,
    },
];

export default BLOG_POSTS;
